AP372A - Compositions containining fialurdine, for the treatment of infection and disease caused by hepatitis B virus (HBV). - Google Patents

Compositions containining fialurdine, for the treatment of infection and disease caused by hepatitis B virus (HBV). Download PDF

Info

Publication number
AP372A
AP372A APAP/P/1993/000513A AP9300513A AP372A AP 372 A AP372 A AP 372A AP 9300513 A AP9300513 A AP 9300513A AP 372 A AP372 A AP 372A
Authority
AP
ARIPO
Prior art keywords
fiau
metabolite
prodrug
hepatitis
patients
Prior art date
Application number
APAP/P/1993/000513A
Other languages
English (en)
Other versions
AP9300513A0 (en
Inventor
Dennis W Adair
Kenneth A Smiles
Dannie King
Original Assignee
Oclassen Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oclassen Pharma Inc filed Critical Oclassen Pharma Inc
Publication of AP9300513A0 publication Critical patent/AP9300513A0/xx
Application granted granted Critical
Publication of AP372A publication Critical patent/AP372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1993/000513A 1992-04-06 1993-04-02 Compositions containining fialurdine, for the treatment of infection and disease caused by hepatitis B virus (HBV). AP372A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86389092A 1992-04-06 1992-04-06
US95292792A 1992-09-25 1992-09-25
US07/959,004 US5432165A (en) 1992-04-06 1992-10-09 Methods for the treatment of infection caused by Hepatitis B virus (HBV)

Publications (2)

Publication Number Publication Date
AP9300513A0 AP9300513A0 (en) 1993-04-30
AP372A true AP372A (en) 1994-11-24

Family

ID=27420427

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000513A AP372A (en) 1992-04-06 1993-04-02 Compositions containining fialurdine, for the treatment of infection and disease caused by hepatitis B virus (HBV).

Country Status (26)

Country Link
US (1) US5432165A (zh)
EP (1) EP0565412A1 (zh)
JP (1) JPH069403A (zh)
CN (1) CN1081879A (zh)
AP (1) AP372A (zh)
AU (1) AU662804B2 (zh)
BE (1) BE1009181A5 (zh)
BR (1) BR9306207A (zh)
CA (1) CA2092356A1 (zh)
EE (1) EE9400068A (zh)
ES (1) ES2105923B1 (zh)
FR (1) FR2689398B1 (zh)
GR (1) GR930100111A (zh)
IL (1) IL105169A0 (zh)
IT (1) IT1264332B1 (zh)
LV (1) LV10191B (zh)
MD (1) MD940152A (zh)
MX (1) MX9301922A (zh)
NO (1) NO931246L (zh)
NZ (1) NZ247188A (zh)
OA (1) OA10102A (zh)
PH (1) PH31116A (zh)
PT (1) PT101238A (zh)
SI (1) SI9300144A (zh)
WO (1) WO1993019762A1 (zh)
YU (1) YU23993A (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (zh) *
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Also Published As

Publication number Publication date
SI9300144A (en) 1994-03-31
IL105169A0 (en) 1993-07-08
AU3530293A (en) 1993-10-07
ES2105923B1 (es) 1998-07-01
FR2689398A1 (fr) 1993-10-08
WO1993019762A1 (en) 1993-10-14
PH31116A (en) 1998-02-28
EE9400068A (et) 1995-12-15
NZ247188A (en) 1995-05-26
LV10191A (lv) 1994-10-20
BR9306207A (pt) 1998-06-23
ITTO930226A0 (it) 1993-04-05
BE1009181A5 (fr) 1996-12-03
NO931246L (no) 1993-10-07
YU23993A (sh) 1997-05-28
FR2689398B1 (fr) 1994-11-18
IT1264332B1 (it) 1996-09-23
LV10191B (en) 1995-04-20
MD940152A (ro) 1995-12-31
GR930100111A (el) 1993-12-30
ITTO930226A1 (it) 1994-10-05
CN1081879A (zh) 1994-02-16
ES2105923A1 (es) 1997-10-16
EP0565412A1 (en) 1993-10-13
AP9300513A0 (en) 1993-04-30
MX9301922A (es) 1993-10-01
NO931246D0 (no) 1993-03-31
CA2092356A1 (en) 1993-10-07
PT101238A (pt) 1994-03-31
US5432165A (en) 1995-07-11
OA10102A (en) 1996-12-18
JPH069403A (ja) 1994-01-18
AU662804B2 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
JP2829545B2 (ja) ２’３’―ジデオキシイノシンによるヒトのレトロウィルス感染症の治療
EP0286224B1 (en) Treatment of human viral infection by dsrna combined with viral inhibitors
AP372A (en) Compositions containining fialurdine, for the treatment of infection and disease caused by hepatitis B virus (HBV).
EA015145B1 (ru) Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
TW200914031A (en) Pharmaceutical composition comprising a SGLT2 inhibitor
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
EA000626B1 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
EP0482081B1 (en) Antiviral composition
TW469132B (en) Antiviral combinations
Sperling Zidovudine.
AU628113B2 (en) 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
EP1113802B1 (en) Antiviral combinations of lamivudine and adefovir
US6432966B2 (en) Antiviral combinations
Lemberg et al. Tolerabilities of antiretrovirals in paediatric HIV infection
US6040298A (en) Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
EP0082667A1 (en) Pharmaceutical compositions
Fletcher et al. Advances in pharmacotherapy: treatment of HIV infection
WO2000016754A2 (en) Antiviral combinations comprising lamivudine and lobucavir
AU660673B2 (en) Treatment of human viral infection by dsRNA combined with viral inhibitors
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
Broder Potential Mechanisms of Action Against HIV
PT92573A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de nucleosidos e polissulfato de pentosano
JPH1045598A (ja) ウイルス感染症予防治療剤